AbbVie hits fresh high after Apogee deal, analysts lift stock targets
27.06.2026 - 10:08:03 | ad-hoc-news.de
By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-27, 10:07.
AbbVie Inc. (US00287Y1091) continues to attract investor attention on the NYSE. The large cap pharma group trades close to a new all-time high after agreeing to acquire Apogee Therapeutics and confirming its regular cash dividend, according to recent market commentary and company statements. Investing.com coverage of AbbVie’s record level
What the latest numbers show
AbbVie shares closed at around 251.52 US dollars on the NYSE on June 26, 2026, up roughly 3.5 percent on the day according to several price services. MarketBeat price and performance data for AbbVie This level is above the recently reported all-time high mark of 245.26 dollars, reflecting a strong run in the stock over the past year, with a one-year return quoted at about 34.4 percent. Investing.com analysis of AbbVie’s share performance
Recent trading data indicate a market capitalization of roughly 430 to 445 billion dollars for AbbVie, placing it among the larger constituents in the S&P 500 healthcare segment. TradingKey snapshot on AbbVie The stock has also shown a marked short-term move, with some technical services noting a gain of more than 17 percent over the past 30 days, underlining the current momentum. TrendSpider technical overview for ABBV
Analysts respond to Apogee acquisition
The market reaction is closely tied to AbbVie’s announced definitive agreement to acquire Apogee Therapeutics for 135.11 dollars per share in cash, valuing the transaction at about 10.9 billion dollars. Investing.com report on the Apogee deal The boards of both companies have approved the deal, which is expected to close in the third quarter of 2026 subject to customary closing conditions and regulatory approvals. Investing.com coverage of recent AbbVie developments
Apogee brings a pipeline of clinical-stage candidates for inflammatory and immunological diseases, including programs in atopic dermatitis and asthma, which fits AbbVie’s focus on immunology. Investing.com pipeline description Following the announcement, Canaccord Genuity lifted its price target for AbbVie to 273 dollars while maintaining a Buy rating, explicitly citing the acquisition’s potential to support long-term growth. Analyst summary of Canaccord’s updated view on AbbVie
Other houses have taken a more measured stance. Cantor Fitzgerald reiterated an Overweight rating with a 240 dollar price target, pointing to a projected 100 to 150 basis point improvement in top-line growth over the 2031-2035 period as the Apogee assets are integrated. Cantor Fitzgerald commentary on AbbVie Bernstein SocGen Group maintained a Market Perform rating and set its target at 225 dollars, reflecting a more cautious view on valuation despite acknowledging the strategic fit of the acquisition. Bernstein SocGen assessment of AbbVie
All news and analysis on the AbbVie shares
Further updates on AbbVie’s share price, acquisitions and pipeline progress are collected in the dedicated topic section and on the company’s investor relations page.
Dividend and earnings calendar
Alongside the Apogee announcement, AbbVie’s board declared a quarterly cash dividend of 1.73 dollars per share, payable on August 14, 2026, to shareholders of record on July 15, 2026. Dividend details reported by Investing.com Data from InvestingPro indicate that AbbVie has raised its dividend for 13 consecutive years, signalling a consistent shareholder payout policy in line with its status as a major dividend name in the S&P 500.
Several tracking services list the next earnings date as July 30, 2026, which will provide further clarity on how the company’s core immunology and oncology franchises are performing relative to expectations. TrendSpider earnings calendar entry for AbbVie Consensus data on various platforms still characterise AbbVie as a Buy-rated stock overall, with average price targets clustered in the mid-250 dollar range, although there is a spread between more optimistic and more cautious houses. TradingKey summary of analyst views on AbbVie
The product behind the stock
AbbVie generates most of its revenue from immunology and oncology therapies, including key branded drugs such as Humira and newer agents like Skyrizi and Rinvoq. Investing.com note on Skyrizi’s indications Recent updates highlight U.S. Food and Drug Administration approvals for Skyrizi in additional patient groups, such as pediatric patients with moderate-to-severe plaque psoriasis or active psoriatic arthritis, extending the product’s addressable market. Description of Skyrizi’s pediatric approval
Where the stock trades today
The AbbVie shares (US00287Y1091) trade on the NYSE under the ticker ABBV and last closed at around 251.52 US dollars on 2026-06-26, 16:00 Eastern Time, according to multiple exchange and data sources.
Key data on the AbbVie shares
- Company: AbbVie Inc.
- ISIN: US00287Y1091
- WKN: A1J84E
- Ticker: ABBV
- Trading venue: NYSE
- Price (as of 2026-06-26, 16:00): 251.52 USD
- Market cap: 445.16 billion USD (as of 2026-06-26)
- Sector / industry: Healthcare – Pharmaceuticals
- Index membership: S&P 500
- Next earnings date: 2026-07-30
Disclaimer: This text is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell securities, or any other form of financial guidance. All data are based on sources deemed reliable at the time of publication, but accuracy and completeness cannot be guaranteed.
